Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Identifying key axis to modulate CD8 T cell exhaustion and improve cancer immunotherapy

Project description

Reprogramming T-cells to boost cancer immunotherapy

Immunotherapy fails for many patients because their T-cells lose their ability to fight tumours. The ERC-funded TREAT project aims to explore a middle-ground cell type known as the ‘intermediate exhausted’ T-cell, which can still respond to treatment and kill cancer cells. By combining CRISPR genetic screening with single-cell multiomics, the project expects to identify the exact signals that create these cells. By controlling these pathways, the project intends to reprogram exhausted T-cells into durable, protective states, significantly improving the performance of checkpoint inhibitors.

Objective

Cancer Immunotherapy has revolutionized Clinical Oncology. Yet, CD8 T-cell exhaustion remains a leading cause of treatment failure. This hypofunctional program suppresses anti-tumor CD8 T-cell responses and is reinforced by a stable epigenetic program that prevents exhausted CD8 T-cells (Tex) from reverting to more functional states. Checkpoint inhibitors such as anti-PD-1 can temporally relieve some constraints on TEX and be curative. However, this approach alone does overcome the epigenetic restraints of exhaustion which likely explains the lack of long-term benefits in many patients. Combinatorial approaches are needed to achieve durable protection in more patients. Yet, an incomplete understanding of TEX biology has provided little rationale for relevant therapeutic interventions.
Recent identification of an “effector-like” subset of TEX (TEX intermediate; TEXint) that mediates the benefits of PD-1 therapy and partially escapes the epigenetic strains of exhaustion, has brought new therapeutic perspective. Indeed, manipulating key pathways related to TEXint cells formation such as the IL-2/Stat5a axis potentiates TEX responses to PD-1 blockade and partially reprogram these cells towards more durably protective cell states. These findings provide compelling proof-of-concept that targeting key pathways driving Texint cell formation can unlock new strategies to overcome exhaustion and bolster PD-1 therapy.
Building on this novel concept, our proposal utilizes advanced murine models alongside molecular engineering, large-scale genetic perturbation tools (CRISPR), and single-cell multiomics to uncover and characterize new regulatory pathways for Texint cell development. Our goal is to unveil new strategies to improve PD-1 therapy and advance next-generation anti-cancer immunotherapies.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

UNIVERSITAT BASEL
Net EU contribution
€ 1 518 750,00
Address
PETERSPLATZ 1
4051 Basel
Switzerland
Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 518 750,00

Beneficiaries (1)